315706-13-9

Basic information

• Product Name: 4EGI-1
• Synonyms: 4EGI-1;α-[2-[4-(3,4-Dichlorophenyl)-2-thiazolyl]hydrazinylidene]-2-nitro-benzenepropanoic acid;eIF4E/eIF4G Interaction Inhibitor, 4EGI-1;4EGI-1, >=98%;alpha-[2-[4-(3,4-Dichlorophenyl)-2-thiazolyl]hydrazinylidene]-2-nitrobenzenepropanoic acid;2-((4-(3,4-Dichlorophenyl)thiazol-2(3H)-ylidene)hydrazono)-3-(2-nitrophenyl)propanoic acid;4EGI-1/4EGI1
• CAS NO: 315706-13-9
• Molecular Formula: C₁₈H₁₂Cl₂N₄O₄S
• Molecular Weight: 451.29
• EINECS: 2017-001-1
• Product Categories: Inhibitors
• Mol File: 315706-13-9.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 668.9±65.0 °C(Predicted)
• Appearance: /
• Density: 1.58±0.1 g/cm3(Predicted)
• Solubility: ≥22.56 mg/mL in DMSO
• PKA: 0.89±0.41(Predicted)
• CAS DataBase Reference: 4EGI-1(CAS DataBase Reference)
• NIST Chemistry Reference: 4EGI-1(315706-13-9)
• EPA Substance Registry System: 4EGI-1(315706-13-9)

Safety Data

• Hazardous Substances Data: 315706-13-9(Hazardous Substances Data)

Usage

Description

4EGI-1, an eIF4E/eIF4G interaction inhibitor, is a compound that plays a crucial role in the regulation of mRNA translation in eukaryotes. It directly binds to the cap-binding protein eIF4E, competitively inhibiting its association with the multidomain adaptor protein eIF4G, which is essential for cap-dependent translation. This interaction is vital for the expression of oncogenic proteins in mammalian cancer cells, and by blocking it, 4EGI-1 can induce apoptosis. Additionally, research suggests that 4EGI-1 may have implications in memory consolidation and autism spectrum disorders due to its effect on the eIF4E/eIF4G interaction. Furthermore, it has the potential to block translation in certain viruses that do not require eIF4E or a cap structure for initiation.

Uses

Used in Pharmaceutical Industry:
4EGI-1 is used as an eIF4E/eIF4G interaction inhibitor for its potential role in preventing the expression of oncogenic proteins in mammalian cancer cells, leading to apoptosis. This makes it a promising candidate for the development of cancer therapeutics.
Used in Memory Consolidation Research:
4EGI-1 is used as a research tool to study the role of normal eIF4E/eIF4G interaction in memory consolidation, providing insights into the molecular mechanisms underlying this cognitive process.
Used in Autism Spectrum Disorder Research:
4EGI-1 is used as a research tool to investigate the relationship between excess eIF4E/eIF4G interaction and autism spectrum disorders, potentially contributing to the understanding of the molecular basis of these conditions.
Used in Antiviral Research:
4EGI-1 is used as an inhibitor to study its potential to block translation in some viruses that do not require eIF4E or a cap structure for initiation, which could lead to the development of novel antiviral strategies.
Used in TRAIL-induced Apoptosis Enhancement:
4EGI-1 is used as an amplifier of TRAIL-induced apoptosis via the down-regulation of FLIPS/L and induction of DR5, which may have applications in cancer therapy by enhancing the effectiveness of TRAIL-based treatments.

references

[1] moerke n j, aktas h, chen h, et al. small-molecule inhibition of the interaction between the translation initiation factors eif4e and eif4g. cell, 2007, 128(2): 257-267.

Upstream product

• 312303-66-5 4-(3,4-dichloro-phenyl)-thiazol-2-yl-hydrazine 
• 5461-32-5 o-nitrophenylpyruvic acid 

Downstream Products

• 901787-88-0 2-(2-(4-(3,4-dichlorophenyl)thiazol-2-yl)hydrazono)-3-(2-nitrophenyl)propanoic acid 
• 901787-86-8 2-(2-(4-(3,4-dichlorophenyl)thiazol-2-yl)hydrazono)-3-(2-nitrophenyl)propanoic acid 
• 901788-22-5 2-{N'-[4-(3,4-Dichloro-phenyl)-thiazol-2-yl]-hydrazino}-3-(2-nitro-phenyl)-propan-1-ol 

Relevant articles and documents

REGULATION OF PROTEIN SYNTHESIS

A composition and method for inhibiting proliferation of a tumor cell compared to a non-tumor cell. Also described are methods of screening for a composition that inhibits cap-dependent translation compared to cap-independent translation of proteins